Beta blockers in older persons with heart failure: tolerability and impact on quality of life
- PMID: 12433890
- PMCID: PMC1767441
- DOI: 10.1136/heart.88.6.611
Beta blockers in older persons with heart failure: tolerability and impact on quality of life
Abstract
Objective: To determine tolerability and symptom changes associated with the introduction of bisoprolol treatment in older patients with heart failure.
Design: Prospective observational cohort study.
Setting: Geriatric medicine outpatient department of a university hospital.
Patients: 51 patients (mean age 78 years, range 70-89 years) with stable symptomatic heart failure caused by left ventricular systolic dysfunction.
Interventions: Bisoprolol tablets, 1.25-10.0 mg.
Main outcome measures: Tolerability; changes in symptoms and exercise tolerance.
Results: 69% of patients tolerated bisoprolol. Mean tolerated dose was 7.6 mg. There was no change in symptoms or exercise capacity in those who tolerated bisoprolol. Perceived health status and symptoms of anxiety and depression improved during the titration period.
Conclusions: The rate of withdrawal from bisoprolol treatment in older patients with congestive heart failure was twice that previously reported in younger patients. The mean tolerated dose was similar to that found in trials reporting clinical efficacy. There was no evidence of a negative impact on symptoms or exercise capacity in patients who tolerated bisoprolol.
Figures
Similar articles
-
Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.Cardiovasc Ther. 2016 Jun;34(3):172-9. doi: 10.1111/1755-5922.12185. Cardiovasc Ther. 2016. PMID: 27003232
-
Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.Korean J Intern Med. 2016 Mar;31(2):277-87. doi: 10.3904/kjim.2015.043. Epub 2016 Feb 16. Korean J Intern Med. 2016. PMID: 26879662 Free PMC article.
-
Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.Cardiology. 2004;102(3):160-5. doi: 10.1159/000080485. Epub 2004 Aug 27. Cardiology. 2004. PMID: 15334027 Clinical Trial.
-
Bisoprolol for congestive heart failure.Expert Opin Pharmacother. 2008 Feb;9(2):293-300. doi: 10.1517/14656566.9.2.293. Expert Opin Pharmacother. 2008. PMID: 18201151 Review.
-
Role of beta-blocker therapy in heart failure and atrial fibrillation.Card Electrophysiol Rev. 2003 Sep;7(3):236-42. doi: 10.1023/B:CEPR.0000012390.43937.2c. Card Electrophysiol Rev. 2003. PMID: 14739721 Review.
Cited by
-
New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging.Front Pharmacol. 2018 Aug 10;9:904. doi: 10.3389/fphar.2018.00904. eCollection 2018. Front Pharmacol. 2018. PMID: 30147654 Free PMC article. Review.
-
Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients.Sci Rep. 2019 Jan 24;9(1):453. doi: 10.1038/s41598-018-37520-8. Sci Rep. 2019. PMID: 30679746 Free PMC article.
-
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.Clin Res Cardiol. 2008 Sep;97(9):578-86. doi: 10.1007/s00392-008-0681-6. Epub 2008 Jun 9. Clin Res Cardiol. 2008. PMID: 18542839 Clinical Trial.
-
Benefits of heart failure-specific pharmacotherapy in frail hospitalised patients: a cross-sectional study.BMJ Open. 2022 Sep 19;12(9):e059905. doi: 10.1136/bmjopen-2021-059905. BMJ Open. 2022. PMID: 36123054 Free PMC article.
-
Adverse drug events and associated factors in heart failure therapy among the very elderly.Can Geriatr J. 2011 Dec;14(4):79-92. doi: 10.5770/cgj.v14i4.19. Epub 2011 Dec 12. Can Geriatr J. 2011. PMID: 23251319 Free PMC article.
References
-
- CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13. - PubMed
-
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001–7. - PubMed
-
- Sharpe N. Benefit of β-blockers for heart failure: proven in 1999. Lancet 1999;353:2000. - PubMed
-
- Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure: a population based study. Eur Heart J 1999;6:421–8. - PubMed
-
- Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208–25. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical